European committee takes a second look at Alzheimer’s drug and now says it should be approved
A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...
Pharmaceutical Technology51m
EMA rethinks stance, committee now recommends Leqembi for Alzheimer’s disease
The EMA’s Committee for Medicinal Products for Human Use has issued a positive recommendation for Eisai and Biogen’s Leqembi ...
EU regulator backs Eisai-Biogen Alzheimer's drug after initial rejection
The European Union's drugs regulator on Thursday recommended approval of Eisai and Biogen's Leqembi for some patients with ...
Biogen’s stock rises after E.U. regulator reverses negative view of Alzheimer’s drug
Biogen’s stock rose 1% Thursday, after Europe’s pharmaceutical regulator issued a positive opinion on the Alzheimer’s disease ...
WKBW1h
Alzheimer's Awareness Month: Grand Island couple shares experience with disease
November is Alzheimer's Awareness Month and 7 News met Grand Island couple Tom and Michele Drabik, who shared their experience with the disease.
EurekAlert!1h
New insight into brain stability: the key role of NMDA receptors
Researchers at Tel Aviv University have made a fundamental discovery: the NMDA receptor (NMDAR)—long studied primarily for ...
AFP on MSN1h
European watchdog partially approves new Alzheimer's drug
Europe's medicines watchdog on Thursday partially approved a marketing request for a long-awaited new treatment for Alzheimer ...
Medscape1h
Infection Plus Pollution Equals Increased Alzheimer’s Risk
The AD risk factors/hits include high exposure to traffic-related air pollution (TRAP) and infections, as well as factors ...
STAT2h
Changing course, European regulators now say Alzheimer’s treatment Leqembi should be approved
Reversing an earlier decision, European regulators recommended that an Alzheimer’s therapy from Eisai and Biogen should be ...
Biogen, Eisai Win CHMP Backing of Leqembi Alzheimer's Drug
A key European regulatory panel has reversed course and is now recommending approval of Leqembi, the Alzheimer's drug from Biogen and Eisai. The companies on Thursday said the European Medicines ...
Is Alzheimer’s Disease the new ‘Type 3’ diabetes?
Because November is Diabetes and Alzheimer’s awareness month, we are learning about the link between brain health and insulin ...
ALZFORUM2h
Tau Modification Drugs Take a Hit with Negative Trial
Taking Out OGA. The rationale behind small-molecule OGA inhibition is that these drugs will decrease tau hyperphosphorylation and aggregation into neurofibrillary tangles (right). [Courtesy of Eli ...